8/28/2008

XDx has received FDA approval to market AlloMap, a blood test designed to help doctors monitor potential organ rejection in heart-transplant patients without the need for repeated biopsies. The test uses blood samples to analyze certain genetic information in white blood cells.

Full Story:
FDAnews, Yahoo!

Related Summaries